erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer

Abstract

The hypothesis that patients whose breast tumors exhibit high erbB-2 expression benefit from dose-intensive CAF should be further validated before clinical implementation. Interactions between erbB-2 expression, p53 expression, and CAF dose underscore the complexities of predictive markers where multiple interactions may confound the outcome.